Biosimilar biologics do not always reduce out-of-pocket costs
Biosimilar competition is not consistently associated with lower out-of-pocket (OOP) costs for commercially insured outpatients, according to a study published online March 29 in JAMA Health Forum.
Apr 2, 2024
0
0